Allogene Therapeutics (ALLO) Current Assets (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Current Assets data on file, last reported at $273.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 6.27% year-over-year to $273.3 million; the trailing twelve-month figure through Mar 2026 stood at $273.3 million (down 6.27% YoY), and the FY2025 full-year result was $257.7 million, down 15.04% from the prior year.
• Current Assets advanced to $273.3 million in Q1 2026, from $257.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $569.1 million in Q3 2022 to a low of $257.7 million in Q4 2025.
• A 5-year average of $401.4 million and a median of $457.1 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets advanced 13.17% in 2022 and tumbled 38.17% in 2025, its largest moves.
• Tracing ALLO's Current Assets over 5 years: stood at $528.8 million in 2022, then retreated by 13.18% to $459.1 million in 2023, then plunged by 33.92% to $303.4 million in 2024, then decreased by 15.04% to $257.7 million in 2025, then rose by 6.03% to $273.3 million in 2026.
• Business Quant data shows ALLO's Current Assets at $273.3 million in Q1 2026, $257.7 million in Q4 2025, and $260.7 million in Q3 2025.